Abstract |
Other groups have reported a superior antitumor efficacy of polyethylene glycol-modified interleukin-2 (PEG-IL-2) compared with regular recombinant interleukin-2 (rIL-2). However, detailed comparison of the antitumor efficacies of locally applied PEG-IL-2 and rIL-2 in the well-established DBA/2-SL2 model shows a higher antitumor efficacy of PEG-IL-2 only at doses < 800 micrograms IL-2 protein/kg body weight. At doses > 800 micrograms IL-2 protein/kg body weight, rIL-2 has better therapeutic efficacy. The superiority of rIL-2 at doses > 800 micrograms IL-2 protein/kg body weight is a result of the toxicity of PEG-IL-2 at these doses. With either IL-2 preparation, cure rates of approximately 90% can be obtained at nontoxic doses. We conclude that PEG-IL-2 does not have superior antitumor efficacy to rIL-2. The main advantage of PEG-IL-2 is that for optimal therapeutic efficacy a daily injection schedule is not required as seems to be the case for rIL-2.
|
Authors | M R Bernsen, H F Dullens, W Den Otter, P M Heintz |
Journal | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
(J Interferon Cytokine Res)
Vol. 15
Issue 7
Pg. 641-5
(Jul 1995)
ISSN: 1079-9907 [Print] United States |
PMID | 7553236
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Interleukin-2
- Recombinant Proteins
- interleukin-2, polyethylene glycol-modified
- Polyethylene Glycols
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use, toxicity)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Evaluation Studies as Topic
- Female
- Injections
- Interleukin-2
(analogs & derivatives, therapeutic use, toxicity)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Mice
- Mice, Inbred DBA
- Neoplasm Transplantation
- Polyethylene Glycols
- Random Allocation
- Recombinant Proteins
(therapeutic use, toxicity)
|